SpeechVive

SpeechVive operates in a focused segment of assistive health technology: Parkinson’s-related speech-volume and communication impairment. Its positioning differs from general speech-to-text, voice assistants, and broad consumer audio products because the core intervention is a wearable device intended to increase vocal volume and clarity during live communication. The companion iOS app adds a candidacy-assessment and demonstration layer, potentially allowing patients or clinicians to evaluate expected benefit before using the hardware. The company’s categories—Assistive Technology, Health Care, and Wellness—place it closer to condition-specific medical-device and digital-health providers than to mainstream voice-interface companies. However, the available profile does not identify named direct competitors, market-share data, regulatory milestones, reimbursement coverage, or comparative clinical outcomes. That limits confidence in assessing its relative commercial position. SpeechVive’s $4.96 million in disclosed funding and three listed current positions indicate a small-scale operating profile, while the 2014 Series A, 2016 seed and grant financing, and 2020 convertible note show a long development cycle supported by both institutional and mission-oriented capital. Its primary differentiator is the combination of targeted Parkinson’s speech support, wearable intervention, and app-based assessment.

SpeechVive’s funding history suggests gradual development from early commercialization toward a larger growth effort. The company was founded in 2011, raised a $700,000 Series A on Apr 2, 2014, and received $975,000 in seed funding plus a $1.3 million grant on May 18, 2016. It then added a $489,998 seed round on Mar 20, 2020 and a $1.5 million convertible note on Jul 7, 2020. The 2020 financing was the largest disclosed financing event and was syndicated among Elevate Ventures, Sidecar Angels, Purdue Foundry Investment Fund, and SWAN Impact Network. Product development has produced two linked offerings: the SpeechVive Device, a wearable speech aid, and the SpeechVive App, an iOS simulation and candidacy tool. The available employee data shows three current positions and no hiring news, so there is limited evidence of workforce expansion. There are also no documented financing events after July 2020, product launches with dated announcements, or executive changes beyond the listed leadership team. Overall, the trajectory reflects a specialized, capital-efficient medical-device company with an extended development path, but its post-2020 growth rate and commercialization scale remain unclear.